These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17582853)

  • 41. Drug treatment of obesity.
    Bray GA
    Psychiatr Clin North Am; 2005 Mar; 28(1):193-217, ix-x. PubMed ID: 15733619
    [No Abstract]   [Full Text] [Related]  

  • 42. The fat of the matter.
    Nat Med; 2012 Aug; 18(8):1155. PubMed ID: 22869166
    [No Abstract]   [Full Text] [Related]  

  • 43. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute pancreatitis in dogs.
    Mod Vet Pract; 1974 Sep; 55(9):759-61. PubMed ID: 4419108
    [No Abstract]   [Full Text] [Related]  

  • 45. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of obesity in the dog.
    Edney AT
    Vet Med Small Anim Clin; 1974 Jan; 69(1):46 passim. PubMed ID: 4491925
    [No Abstract]   [Full Text] [Related]  

  • 48. Owners' perceptions of their dogs.
    Vogel CJ
    Vet Rec; 2007 Dec; 161(23):796. PubMed ID: 18065822
    [No Abstract]   [Full Text] [Related]  

  • 49. Opportunities and challenges for the development of pharmacological therapies for obesity treatment.
    Cawthorne MA
    Obes Rev; 2007 Mar; 8 Suppl 1():131-6. PubMed ID: 17316316
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment modalities of obesity: what fits whom?
    Hainer V; Toplak H; Mitrakou A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S269-77. PubMed ID: 18227496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a bioelectric impedance device in obese and lean healthy dogs to estimate body fat percentage.
    Stone R; Berghoff N; Steiner J; Zoran D
    Vet Ther; 2009; 10(1-2):59-70. PubMed ID: 19742449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide.
    Krentz AJ; Fujioka K; Hompesch M
    Drugs; 2015 Jun; 75(9):931-3. PubMed ID: 25963328
    [No Abstract]   [Full Text] [Related]  

  • 53. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Obesity: the fat lady sings?
    Cairns E
    Drug Discov Today; 2005 Mar; 10(5):305-7. PubMed ID: 15749277
    [No Abstract]   [Full Text] [Related]  

  • 55. The good and the bad news: surgery vs. drug therapy.
    Astrup A
    Obes Rev; 2008 Jan; 9(1):1-3. PubMed ID: 18154599
    [No Abstract]   [Full Text] [Related]  

  • 56. One pill makes you smaller: the demand for anti-obesity drugs.
    Cawley J; Rizzo JA
    Adv Health Econ Health Serv Res; 2007; 17():149-83. PubMed ID: 19548552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychological correlates of obesity in women.
    van der Merwe MT
    Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S14-8; discussion S31-2. PubMed ID: 17968432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A contribution to the occurrence and treatment of obesity in dogs].
    Meyer H; Drochner W; Weidenhaupt C
    Dtsch Tierarztl Wochenschr; 1978 Apr; 85(4):133-6. PubMed ID: 346342
    [No Abstract]   [Full Text] [Related]  

  • 59. [Advertisement Palfium = Palface].
    Hellebrekers LJ; Pellicaan CH
    Tijdschr Diergeneeskd; 2001 May; 126(9):331. PubMed ID: 11383368
    [No Abstract]   [Full Text] [Related]  

  • 60. Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
    Tian X; Switzer AG; Derose SA; Mishra RK; Solinsky MG; Mumin RN; Ebetino FH; Jayasinghe LR; Webster ME; Colson AO; Crossdoersen D; Pinney BB; Farmer JA; Dowty ME; Obringer CM; Cruze CA; Burklow ML; Suchanek PM; Dong L; Dirr MK; Sheldon RJ; Wos JA
    J Med Chem; 2008 Oct; 51(19):6055-66. PubMed ID: 18771254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.